Navigation Links
Michael J. Fox Foundation Awards $2.5 Million for Parkinson's Drug Development Projects Led By Academic Investigators
Date:1/27/2009

NEW YORK, Jan. 27 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research has awarded $2.5 million total for seven Parkinson's drug development projects. The funding was awarded under a special, one-time academic funding track of the Foundation's industry-focused Therapeutics Development Initiative.

By funding academic projects under the Therapeutics Development Initiative, the Foundation aims to leverage the increasing sophistication of university-based drug discovery/development programs. While academic labs historically have focused the lion's share of their attention on basic research to identify drug targets, it is becoming ever more common for university investigators to engage in translational research efforts. Today, increasing numbers of academic centers are in possession of the core resources and expertise to conduct the highly specialized studies that can keep therapeutic hits moving forward toward clinical testing and patients.

As with all MJFF grants, full funding is dependent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

Funded projects are listed below. Detailed information, including grant abstracts and researcher bios, is available at www.michaeljfox.org.

Modified miRNAs Targeted at Alpha-synuclein as PD Therapy

Asa Abeliovich, MD, PhD, Columbia University

Pre-clinical Characterization of 5-HT1A/1B Receptor Agonists for the Treatment of L-DOPA-induced Dyskinesia

Manolo Carta, PhD, Lund University, Sweden

Novel Alpha-synuclein Isomers as Immunogens for Immunotherapy of Parkinson's Disease

Rowen Chang, PhD, and Chuantao Jiang, MD, PhD, University of Texas Medical School at Houston

Characterization and Validation of a C.Elegans LRRK2 Model of PD

Shu Chen, PhD, and Amy Wilson-Delfosse, PhD, Case Western Reserve University

Effects of KCNQ (Kv7) Channel Openers in Levodopa-induced Dyskinesias Angelika Richter, PhD, Freie Universitat Berlin, Germany

Identification of a Novel Calcium Selective Antagonist for Neuroprotection in PD

D. James Surmeier, PhD, and Richard Silverman, PhD, Northwestern University

Structural and Chemical Approaches to Understand and Modulate LRRK2 Kinase Activity in Parkinson's Disease

Zhenyu Yue, PhD, Ming-Ming Zhou, PhD, and Iban Ubarretxena-Belandia, PhD, Mount Sinai School of Medicine

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within the coming decade through an aggressively funded research agenda. The Foundation has funded over $137 million in research to date.

    CONTACT:
    Media: Holly Barkhymer
    (212) 509-0995 x242
    hbarkhymer@michaeljfox.org
    Research: Brian Fiske, PhD
    (212) 509-0995 x203
    bfiske@michaeljfox.org


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Michael Moores SiCKO Becomes the Third Highest Grossing Documentary of All Time Surpassing An Inconvenient Truth
2. Katie Hood Appointed Interim Chief Executive Officer of Michael J. Fox Foundation
3. Clarient Names Michael J. Pellini, M.D. Chief Operating Officer
4. Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director
5. Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008
6. BioElectronics Corporation Announces Addition of Michael Seidenman, R.Ph. as Vice President of Sales
7. BioSeek Appoints Michael C. Venuti, Ph.D., Chief Executive Officer
8. Irene Hegeman Richard, MD, Appointed Senior Medical Advisor to The Michael J. Fox Foundation
9. Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes Behavioral Mental Health Summit
10. Michael J. Fox Foundation Launches Rapid Response Innovation Awards 2008 Following Strong Inaugural Year Response
11. Siemens Medical Solutions Michael Long Recognized as one of Computerworlds 2008 Premier 100 IT Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... ... Harbour , a DAO (decentralized autonomous organization) that harnesses the wisdom of ... technical specifications . , 2017 has seen an explosion of token launches by blockchain ... will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, said, “We ...
(Date:6/27/2017)... ... June 27, 2017 , ... From June 20-22, EarQ and Widex ... Syracuse, New York, where EarQ is headquartered. , Together, the organizations educate hearing ... today’s savvy consumer, and the latest in hearing technology. At the event, EarQ ...
(Date:6/27/2017)... ... June 27, 2017 , ... PR ... an upcoming case studies guidebook. This guidebook offers an excellent branding and exposure ... include articles, case studies and how-to’s that fall into the following categories:, ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Hammer Strength, ... Association (NBSCA) have named Javair Gillett of the Houston Rockets the NBSCA Strength & ... the award is decided by NBSCA members who vote to select the coach who ...
(Date:6/27/2017)... ... June 27, 2017 , ... Children’s National Health System ... rankings, with its Neonatology program ranking #1 out of more than 1500 neonatal ... to the coveted Honor Roll, a distinction given to the top performing children’s hospitals ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... 2017  Researchers from DRUGSCAN ® and INC ... a live, complimentary webinar titled, "Untangling methods to tamper ... real world" on Wednesday June 28, 2017 from 12:00 ... webinar will feature interviews with recreational and dependent prescription ... techniques abusers use to prepare opioid tablets for routes ...
(Date:6/14/2017)... , June 14, 2017 The Bio ... City of Fremont and the ... the bio-pharma industry in California ... enabling executive networking, and fostering workforce development. The primary ... and growth of start-ups, as well as small and ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
Breaking Medicine Technology: